David A. Siegel Coherus Bio Sciences, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
Shares
21 transactions
Others Institutions Holding CHRS
# of Institutions
130Shares Held
67.8MCall Options Held
1.68MPut Options Held
91.8K-
Black Rock Inc. New York, NY11.8MShares$12.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$12.3 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$5.81 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$5.78 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$4.02 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $85.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...